AAM Slams USMCA Over Mexico Biologics Impact
Doubling Data Exclusivity Will Only Harm Patients, Not Boost Industry
Biologic exclusivity provisions in the proposed USMCA US-Mexico-Canada trade agreement will not create a new market for original biologics in Mexico, as firms have been selling them in the country since before 2001, the US Association for Accessible Medicines has argued in response to brand industry claims.
